Research and innovation in the development of everolimus for oncology Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Drug Resistance, Neoplasm
  • Gene Expression Profiling
  • Interferon-alpha
  • Kidney Neoplasms

abstract

  • The clinical efficacy of everolimus alone and in combination with other agents has been observed in recently completed Phase II-III studies in a wide spectrum of tumors, including RCC, neuroendocrine tumors, tuberous sclerosis complex, SEGAs and angiomyolipomas, lymphoma and gastric, breast and hepatocellular cancers. These findings emphasize the importance of mTOR in diverse cancers and rare diseases and underscore the potential role for everolimus as an effective agent in multiple indications.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1517/17460441.2011.558079

PubMed ID

  • 22647206

Additional Document Info

start page

  • 323

end page

  • 38

volume

  • 6

number

  • 3